Nantahala Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Nantahala Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-67,282	Closed	-$5.65M	–	163
2026 Q1	$5.65M	Sell	67,282 -307,718	-82%	-$17.8M	0.21%	95
2025 Q4	$15.5M	Hold	375,000	–	–	0.51%	48
2025 Q3	$14.8M	Buy	+375,000	New	+$9.58M	0.51%	47
2024 Q1	–	Sell	-328,433	Closed	-$3.42M	–	129
2023 Q4	$3.42M	Sell	328,433 -8,429	-3%	-$93.1K	0.2%	80
2023 Q3	$4.6M	Buy	336,862 +24,362	+8%	+$307K	0.39%	56
2023 Q2	$3.79M	Buy	+312,500	New	+$3.55M	0.37%	58

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Nantahala Capital Management's DNTH Position: Q2 2026 in Review

Nantahala Capital Management sold out of Dianthus Therapeutics (DNTH) in Q2 2026, closing a stake of 67,282 shares — an estimated $5.65M sold.

Nantahala Capital Management first reported a position in DNTH in Q2 2023 and held it in 6 quarters. The position peaked at $15.5M in Q4 2025. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Nantahala Capital Management reported no remaining Dianthus Therapeutics position as of Q2 2026 after selling out during the quarter.
Nantahala Capital Management sold 67,282 Dianthus Therapeutics shares in Q2 2026, an estimated $5.65M.
Nantahala Capital Management first reported a position in Dianthus Therapeutics in Q2 2023 and held it in 6 quarters.
Nantahala Capital Management's Dianthus Therapeutics position peaked at $15.5M in Q4 2025.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.